StephenCRubinMD

PubMed

• 2572 citations
  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
  Lin Zhang, Jose R. Conejo-Garcia, Dionyssios Katsaros, Phyllis A. Gimotty, Marco Massobrio
  The New England Journal of Medicine. 2003-01-16
• 121 citations
  Clinical Characteristics of Clear Cell Carcinoma of the Ovary
  Kian Behbakht, Thomas C. Randall, Ivor Benjamin, Mark A. Morgan, Stephanie A. King
  Gynecologic Oncology. 1998-08-01
• 123 citations
  Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings.
  Stephen C. Rubin, Thomas C. Randall, Katrina Armstrong, Dennis S. Chi, William J. Hoskins
  Obstetrics and Gynecology. 1999-01-01

Journal Articles

• The impact of adjuvant therapy on survival and recurrence patterns in women with early-stage uterine carcinosarcoma: A multi-institutional study  
  Guttman DH, Li H, Sevak P, Grover S, Jacobson G, Feldman A, Rubin S, Chu C, Bhatia S, Eishaikh MA, Lin LL, Int J Gynecol Cancer, 1/1/2016
• Every-3-Week vs Weekly Paclitaxel and Carboplatin for Ovarian Cancer  
  Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL, DiSilvestro PA, Rubin SC, Martin LP, Davidson SA, Huh WK, O’Malley DM, Boente PM, Micheal H, Monk BJ, N Engl J Med, 1/1/2016
• Group-based trajectory modeling of fear of disease recurrence among women recently diagnosed with gynecological cancers  
  Manne SL, Myers-Virtue S, Kissane D, Ozga ML, Kashy DA, Rubin SC, Rosenblum NG, Heckman CJ, Psychooncology, 1/1/2016
• Disparities in the Management and Outcome of Cervical Cancer in the United States According to Health Insurance Status  
  Churilla T, Egleston B, Dong Y, Shaikh T, Murphy C, Mantia-Smaldone G, Chu C, Rubin S, Anderson P, Gynecol Oncol, 1/1/2016
• The role of adjuvant radiation in lymph node positive endometrial adenocarcinoma  
  Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson PR, Gynecol Oncol, 1/1/2016
• Resilience, positive coping, and quality of life among women newly diagnosed with gynecological cancers  
  Manne S, Myers-Virtue S, Kashy D, Ozga M, Kissane D, Heckman C, Rubin SC, Rosenblum N, Cancer Nurs, 1/1/2015
• A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or prima...  
  Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM, Gynecol Oncol, 1/1/2015
• Survival Outcomes Improved in Contemporary Cohort of Patients With Pelvic or Abdominal Recurrence After Treatment for Stage I/II Endometrial Carcinoma  
  Xu MJ1, Chu C, Rubin S, Lin LL, Am J Clin Oncol, 1/1/2015
• Cancer-related concerns among women with a new diagnosis of gynecological cancer  
  Myers-Virtue SB, Manne SL, Ozga M, Kissane DW, Rubin S, Heckman C, Rosenblum N, Graff JJ, Int J Gynecol Cancer, 1/1/2014
• Holding back sharing concerns, dispositional emotional expressivity, perceived unsupportive responses and distress among women newly diagnosed with gynecological cancers  
  Manne S, Myers S, Ozga M, Kissane D, Kashy D, Rubin S, Heckman C, Rosenblum N, Gen Hosp Psychiatry, 1/1/2014
• Risk Factors for Gastrointestinal Adverse Events in a Phase III Randomized Trial of Bevacizumab in First-Line Therapy of Advanced Ovarian Cancer: a Gynecologic Oncolog...  
  Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler JM, Greer B, Boente M, Fleming GF, Lim PC, Rubin S, Karsumata N, Liang SX, J Clin Oncol, 1/1/2014
• Pelvic magnetic resonance imaging diagnosis correlates with pathology of adnexal masses  
  Haggerty AF, Hagemann AR, Chu C ,Siegelman E, Rubin SC, Int J Gynecol Can, 1/1/2014
•  
  Mantia-Smaldone G, Ronner L, Blaie A, Gamerman V, Morse C, Orsulic S, Rubin SC, Gimotty P, Adams S, Gynecol Oncol, 1/1/2014
• Paget Cells on Endometrial and Endocervical Curettings in a Patient With Recurrent Vulvar Paget's Disease  
  Clayton EF, Rubin SC, Dumoff KL, Int J Surg Pathol, 1/5/2013
• Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remi...  
  Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, Vonderheide RH, June CH, Cancer Immunology, Immunotherapy, 1/1/2012
• Therapist and Patient Perceptions of Alliance and Progress In Psychological Therapy for Women Diagnosed with Gynecological Cancers  
  Manne S, Kashy DA, Rubin S, Hernandez E, Bergman C, Journal of Consulting & Clinical Psychology, 1/1/2012
• A phase II trial of thalidomide in patients with refractory uterine carcinosarcoma and correlation with biomarkers of angiogenesis: a Gynecologic Oncology Group study  
  McMeekin DS, Sill MW, Darcy KM, Abulafia O, Hanjani P, Pearl ML, Rubin SC, Rose PG, Small L, Benbrook DM, Gynecol Oncol, 1/1/2012
• Tissue-based immune monitoring I: Tumor core needle biopsies allow indepth interrogation of the tumor microenvironment  
  Hagemann AR, Cadungog M, Hagemann IS, Hammond R, Adams SF, Chu CS, Rubin SC, Zhang L, Addya K, Birrer MJ, Bimotty PA, Coukos G, Cancer Biology & Therapy, 1/1/2011
• Tissue-based immune monitoring II: Multiple tumor sites reveal immunologic homoegeneity in seruos ovarian carcinoma  
  Hagemann AR, Hagemann IS, Cadungog M, Hwang WT, Patel P, Lal P, Hammond R, Gimotty PA, Chu Cs, Rubin SC, Birrer MJ, Powell DJ Jr., Feldman MD, Coukos G, Cancer Biology & Therapy, 1/1/2011
• A high response rate to liposomal dosorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer  
  Adams SF, Marsh EB, Elmasri W, Halberstadt S, Vandecker S, Sammel MD, Bradbury AR, Daly M, Karlan B, Rubin SC, Gynecol Oncol, 1/1/2011
• A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian ,fallopian tube, and p...  
  Morgan MA, Will MW, Fujiwara K, Greer B, Rubin SC, Degeest K, Yamada SD, Waggoner S, Coleman RL, Walker JL, Mannel RS, Gynecol Oncol, 1/1/2011
• Therapy processes and outcomes of psychological interventions for women diagnosed with gynecological cancers: A test of the generic process model of psychotherapy  
  Manne, S., Winkel, G., Zaider, T., Rubin, S., Hernandez, E., & Bergman, C, Consult Clin Psychol, 1/1/2010
• Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers  
  Domchek SM, Friebel TM, Garber JE, Isaacs C, Matloff E, Eeles R, Evans DG, Rubinstein W, Singer CF, Rubin S, Lynch HT, Daly MB, Weitzel J, Ganz PA, Pichert G, Olopade ..., Breast Cancer Research & Treatment, 1/1/2010
• A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study  
  Aghajanian C, Blessing JA, Darcy KM, Reid G, DeGeest K, Rubin SC, Mannel RS, Rotmensch J, Schilder RJ, Riordan W, Gynecologic Oncology Group, Gynecol Oncol, 1/1/2009
• Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study  
  Winter WE 3rd, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG, Rubin SC, Muggia F, McGuire WP, J Clin Oncol, 1/1/2008
• Join now to see all

Books/Book Chapters

• Clinical Gynecologic Oncology 
  Chapter: Basic Principles of chemotherapy 
  Chu CS, Rubin SCEditors: DiSaia and Creasman.Elsevier, Philadelphia, PAEdition 8th,2012
• Obstetric and Gynecologic Emergencies 
  Chapter: Oncologic Emergencies 
  Adams S, Rubin SCEditors: Benrubi G.Churchill Livingstone, New York, NY2010
• Surgery for Ovarian Cancer: Principles and Practice 
  Chapter: Epidemiology, staging, and clinical characteristics 
  Page 1 - 23Chu CS, Rubin SCEditors: Bristow RE, Karlan BY, and Chi DS.Informa Healthcare, New York, NYEdition 2nd,2010
• Surgery for Ovarian Cancer: Principles and Practice 
  Chapter: Ovarian cancer: Epidemiology, staging, and clinical characteristics 
  Chu CS, Rubin SCEditors: Bristow RE, and Karlan BY.Parthenon Publishing Group, Lancaster, UKEdition 2nd,2010
• Principles and Practice of Gynecologic Oncology 
  Chapter: Management of complications of gynecologic cancer treatment 
  Mutch DG, Yashar C, Markman M, Rubin SCEditors: Barakat RR, Markman M, Randall ME.Lippincott Williams and Wilkins, Philadelphia, PAEdition 5th,2009
• Principles and Practice of Oncology 
  Chapter: Cancer of the uterine body 
  Chu CS, Lin LL, Rubin SCEditors: DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Weinberg RA.Lippincott Williams and Wilkins, Philadelphia, PA2008
• Hereditary Gynecologic Cancer: Risk, Prevention, and Management 
  Chapter: Therapy and prognosis of BRCA associated ovarian cancer 
  Page 117 - 127Chu CS, Rubin SCEditors: Lu KH.Informa Healthcare, New York, NY2008
• Cancer: Principles and Practice of Oncology 
  Chapter: Cancer of the uterine body 
  Page 1496 - 1542Chu CS, Lin LL, Rubin SCEditors: DeVita VT, Hellman S, Rosenberg SA.Lippincott Williams & Wilkins, Philadelphia, PAEdition 8th,2008
• Clinical Gynecologic Oncology 
  Chapter: Chemotherapy of gynecologic cancers 
  Chu CS, Rubin SCEditors: DiSaia PJ, Creasman WT.MosbyEdition 7th,2007
• Prognostic and Predictive Factors in Gynecologic Cancers 
  Chapter: Influence of BRCA1 and BRCA2 on ovarian cancer survival 
  Chu CS, Rubin SCEditors: Levenback C, Sood AK, Lu KH, and Coleman RL.Informa Healthcare, London, UK2007
• Surgery for Ovarian Cancer: Principles and Practice 
  Chapter: Ovarian cancer: Epidemiology, staging, and prognostic factors 
  Page 1 - 38Chu CS, Rubin SCEditors: Bristow RE, and Karlan BY.Parthenon Publishing Group, Lancaster, UK2006
• Chemotherapy for Gynecologic Neoplasms: Current Therapy and Novel Approachs 
  Chapter: Chemotherapy for germ cell tumors 
  Page 441 - 458Bandera CA, Rubin SCEditors: Penalver M.Marcel Dekker, New York, NY2004
• Gynecologic Cancer: Controversies in Management 
  Chapter: Management of intestinal obstruction in the terminal patient and management of ascites 
  Page 727 - 742Chu CS, Rubin SCEditors: Gershenson DM, Gore M, McGuire WP, Quinn M, and Thomas G.Elsevier Science, Philadelphia, PA2004
• Ovarian Cancer 
  Chapter: Second-look laparotomy 
  Randall TC, Rubin SCEditors: Rubin SC Sutton GP.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 2nd,2001
• Clinical Management of Ovarian Tumors 
  Chapter: Ovarian cancer presenting as a pelvic mass in a woman under 40 years 
  Morgan MA, Rubin SCEditors: Ledermann JA, Hoskins WJ, Kaye SB, Vergote I.Martin Dunitz, London, UK2001
• Principles and Practice of Gynecologic Oncology 
  Chapter: Management of late effects of treatments 
  Mutch DG, Grisby PW, Markman M, Rubin SCEditors: Hoskins WJ, Perez C, Young R.Lippincott Williams and Wilkins, Philadelphia, PAEdition 3rd,2000
• Treatment of the Postmenopausal Woman 
  Chapter: Patients at high risk for ovarian carcinoma 
  Randall TC, Rubin SCEditors: Lobo.Lippincott-Raven Publishers, Philadelphia, PA1999
• Controversies in the Management of Ovarian Cancer 
  Chapter: Secondary cytoreductive surgery for epithelial ovarian cancer 
  Benjamin I, Rubin SCEditors: Gershenson DM and McGuire WP.Churchill Livingstone, New York, NY1998
• Gynecologic Oncology 
  Chapter: Advances in cytoreductive surgery of gynecologic cancers 
  Benjamin I, Rubin SCEditors: Ozols RF.Kluwer, Boston, MA1998
• Cancer Management: A Multidisciplinary Approach 
  Chapter: Ovarian Cancer 
  Rubin SC, Fennell D, Randall MEEditors: Pazdvr R, Coia LR, Hoskins WJ, Wagman LD.Churchill Livingstone, New York, NYEdition 2nd,1998
• Tumor Board: Case Management 
  Chapter: Stage IIIB epithelial ovarian cancer 
  Rubin SCEditors: Winchester DP, Brennan MF, Dodd GD, Hensen DE, Kennedy BJ, Steele GD Jr, Wilson F.Lippincott-Raven Publishers, Philadelphia, PA1997
• Cancer Management: A Multidisciplinary Approach. PRR 
  Chapter: Ovarian cancer 
  Rubin SC, Fennelly D, Randall MEEditors: Pazdur R, Coia LR, Hoskins WJ, Wagman LD.New York, NY1996
• Expert Consultations in Gynecologic Malignancies 
  Chapter: Second-look laparotomy 
  Menzin AW, Rubin SCEditors: JL and Markman M.Raven Press, New York, NY1996
• Expert Consultations in Gynecologic Malignancies 
  Chapter: Recurrent ovarian dysgerminoma 
  Menzin AW, Rubin SCEditors: JL and Markman M.Raven Press, New York, NY1996
• Textbook of Internal Medicine 
  Chapter: Gynecologic malignancies 
  Morgan MA, Rubin SCEditors: Kelley WN.J.B. Lippincott Co., Philadelphia, PAEdition 3rd,1996
• Join now to see all

Abstracts/Posters

• phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study
  Walker J, Brady MF, DiSilvestro PA, Fujiwara K, Alberts D, Zheng W, Tewari K, Cohn DE, Powell M, Van Le L, Rubin S, Davidson SA, Gray HJ, Waggoner S, Myers T, Aghajani..., Gynecol Oncol, 1/1/2016
• National Cancer Data Base report of associations, patterns, and survival benefit of lymphadenectomy in endometrial cancer
  Cripe II JC, Handorf E, Brown JL, Woodman S, Rubin SC, Jain A, Mantia-Smaldone GM, Gynecol Oncol, 1/1/2016
• Widespread failure to adhere to National Comprehensive Cancer Network guidelines adversely impacts survival for patients with locally advanced cervical cancer
  Brown JL, Handorf E, Cripe II JC, Woodman S, Jain A, Rubin SC, Mantia-Smaldone GM, Gynecol Oncol, 1/1/2016
• The role of adjuvant radiation in lymph node-positive endometrial adenocarcinoma
  Shaikh T, Churilla TM, Mantia-Smaldone GM, Chu C, Rubin SC, Anderson P, Gynecol Oncol, 1/1/2016
• CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study
  Lee TY, Ng C, Zhang Z, Lee S, Marques H, Burgers K, Su F, Bauza J, Mannel R, Walker J, Huh W, Rubin S, DiSilvesto P, Martin L, Chan J, Bookman M, Coleman RL, J Clin Oncol, 1/1/2015
• Quality of care for the initial management of stage IB1-IIA2 invasive cervical carcinomas
  Mantia-Smaldone G, Handorf E, Jain A, Martin LP, Rubin SC, J Clin Oncol, 1/1/2015
• Pelvic magnetic resonance imaging diagnosis correlates with pathology of adnexal masses
  Hagemann AR, Chu C ,Siegelman E, Rubin SC, Gynecol Oncol, 1/1/2014
• Preoperative predictors which impact the survival and outcome of secondary cytoreduction in ovarian cancer
  Rubin SC, Hwang WT, Tanyi J, Gynecol Oncol, 1/1/2014
• A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or prima...
  Sill M, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen HX, Swisher EM, Gynecol Oncol, 1/1/2014
• Phase II Evaluation of the Potent, Highly Selective PARP Inhibitor Veliparib in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary...
  Coleman RL, Sill M, Aghajanian C, Gray HS, Tewari K, Rubin S, Rutherford T, Chan J, Swisher E, Society of Gynecologic Oncologists 44th Annual Meeting, 1/1/2013
• CD8 T cell-mediated immune responses are critical to the increased efficacy of Doxil in BRCA 1 deficient tumors
  Mantia-Smaldone G, Gamerman V, Gimotty P, Loomis R., Orsulic S, Rubin S, CoukosG, Adams S, Society of Gynecologic Oncologists 43rd Annual Meeting, 1/1/2012
• Vaginal Intraepithelial Neoplasia (VAIN) After Radiation Therapy For Gynecologic Malignancies: A Clinically Recalcitrant Entity
  Liao JB, Jean S, Ford AE, Tanyi JL, Hagemann AR, Lin LL, McGrath CM, Rubin SC, 41th Annual Meeting on Women’s Cancer of the Society of Gynecologic Oncologists, San Francisco, CA, 1/14/2010
• Women with germline BRCA mutations show significantly higher response rates and longer survival following treatment with pegylated liposomal doxorubicin (Doxil) for re...
  March E, Adams S, Sammel M, Coukos G, Rubin S, Society of Gynecologic Oncologists 41st Annual Meeting, San Francisco, CA, 1/1/2010
• Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and pr...
  Behbakht K, Sill MW, Darcy KM, Rubin SC, Mannel RS, Waggoner S, Schilder RJ, Cai KQ, Godwin AK, Alpaugh RK, Gynecol Oncol, 1/1/2010
• Adoptive Immunotherapy for Recurrent Ovarian Cancer Using Autologous Whole Tumor Antigen-Primed T Lymphocytes
  Powell DJ, Kandalaft LE, Smith L, Adams S, Liao J, Hagemann A, Tanyi JL, Ye Q, Best A, Torigian D, Chu C, Rubin SC, Bosch M, Levine B, Stadtmauer E, June CH, Coukos G, Journal of Immunotherapy; 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer, Washington, DC, 1/1/2010
• Autologous Whole-Tumor Antigen Combinatorial Immuno-therapy for Recurrent Ovarian Cancer
  Kandalaft LE, Powell DJ, Smith L, Adams S, Liao J, Hagemann A, Tanyi JL, Ye Q, Best A, Torigian D, Chu C, Rubin SC, Bosch M, Levine B, June CH and Coukos G, Journal of Immunotherapy; 25th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer, Washington, DC, 1/1/2010
• A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian ,fallopian tube, and p...
  Morgan M, Sill MW, Fujiwara K, Greer B, Rubin S, De Geest K, Yamada SD, Waggoner S, Coleman R, Walker J, Mannel R, Gynecol Oncol, 1/1/2010
• Effect of raloxifine on endometrial cancer risk in a population-based, case-control study
  Demichele A, Troxel A, Weber A, Berlin J, Bunin G, Turzo E, Burgh D, Schinnar R, Rubin S, Rebbeck T, Strom B, Annual Meeting, American Society of Clinical Oncology, 1/1/2005
• Analysis of Survival Outcomes of Stage I Clear Cell Carcinoma of the Ovary
  Kim S, Morgan M, Coukos G, Rubin S, Chu C, National Gynecologic Oncology Fellow’s Forum, 1/1/2005
• Treatment with vascular endothelial growth factor receptor-2 inhibitor SU5416 in combination with cisplatin or paclitaxel effects tumor growth in mouse ovarian carcino...
  Holtz D, Zhang L, Coureges C, Mohamed A, Benencia F, Conejo-Garcia J, Rubin SC, Coukos G, Society of Gynecologic Oncologists Annual Meeting, 1/1/2004
• A phase III randomized trial of cisplatin and paclitaxel administered by either 24 hour or 96 hour infusion in patients with selected Stage III or Stage IV epithelial ...
  Sprigs D, Brady MF, Rubin SC, Hanley M, Copeland LJ, Clarke-Pearson D, Burger RA, Proc: ASCO, 1/1/2004
• Antitumor immune dysfunction in ovarian carcinoma caused by VEGF-induced upregulation of fas ligand on dendritic cells
  Gray HJ, Mohamed-Hadley A, Coureges C, Benencia F, Conejo-Garcia JR, Zhang L, Rubin SC, Coukos G, The 34th Annual Meeting of the Society of Gynecologic Oncologists, New Orleans, LA, 1/31/2003
• Tyrosine kinases inhibitor SU5416 tumor growth in a syngeneic mouse model of ovarian carcinoma overexpressing VEGF-164
  Rubin SC, Mohamed A, Coureges C, Holtz D, Benecia F, Coukos G, 34th Annual Meeting, Society of Gynecologic Oncologists, 1/1/2003
• Antitumor immune dysfunction in ovarian carcinoma caused by VEGF-induced upregulation of fas ligand cells
  Rubin SC, Hadley-Mohamed A, Coureges C, Benencia F, Coukos G, Gray H, Conejo-Garcia J-R, Zhang L, 34th Annual Meeting, Society of Gynecologic Oncologists, 1/1/2003
• BRCA1 status and survival in women with primary peritoneal carcinoma
  Berkowitz R, Mok S, Rubin SC, Bandera CA, Bell D, Lee H, 34th Annual Meeting, Society of Gynecologic Oncologists, 1/1/2003
• Join now to see all

Lectures

• Hereditary ovarian cancer 
  University of Pittsburgh, Pittsburgh, PA, 2000; Washington University School of Medicine, St. Louis, - 1/1/2007
• Secondary surgery for ovarian cancer 
  Memorial Sloan-Kettering Cancer Center, New York, NY - 1/1/2004
• Hereditary ovarian cancer: Molecular genetics and clinical implications 
  MD Anderson Cancer Center, Houston, TX, 2004; Johns Hopkins School of Medicine, Baltimore, MD, 2008 - 1/1/2004
• Prophylactic oophorectomy 
  Dusseldorf, Germany, 1998; New York, NY, 2003; Memorial Sloan-Kettering Cancer Center, New York, NY, - 1/1/2003
• Molecular genetics of hereditary ovarian cancer 
  Chicago, IL - 1/1/2003
• Chemotherapy in ovarian cancer 
  Turin, Italy - 1/1/2000
• Neoadjuvant chemotherapy in epithelial ovarian cancer 
  San Francisco, CA - 1/1/1999
• BRCA1, BRCA2, and HNPCC gene mutations in an unselected ovarian cancer population 
  Vancouver, Canada - 1/1/1997
• Clinical features of ovarian cancers in women with BRCA1 and BRCA2 mutations 
  Phoenix, AZ - 1/1/1997
• Clinical and pathologic characteristics of ovarian cancer in women with germline mutations of BRCA1 
  New Orleans, LA - 1/1/1996
• Has aggressive cytoreductive surgery improved outcome in ovarian cancer? 
  Norwegian Radium Hospital, Oslo, Norway - 1/1/1995
• Postoperative radiotherapy in high risk endometrial cancer 
  Philadelphia, PA - 1/1/1995
• Neoadjuvant chemotherapy for advanced ovarian carcinoma 
  San Francisco, CA - 1/1/1995
• Adjuvant therapy of early ovarian cancer 
  Montreal, Canada - 1/1/1994
• Second-look laparotomy should be considered a part of the standard management of the patient with advanced ovarian carcinoma 
  Cleveland, OH - 1/1/1994
• Prevalence and significance of HER-2/Neu expression in early epithelial ovarian cancer 
  Irvine, CA - 1/1/1993
• Pharmacokinetics, biodistribution, and intraoperative radioimmunodetection of radiolabeled monoclonal antibody MX35 in patients with epithelial ovarian cancer 
  Irvine, CA - 1/1/1993
• Platinum-based chemotherapy of high risk stage I epithelial ovarian cancer following comprehensive surgical staging 
  Irvine, CA - 1/1/1993
• Second-look laparotomy in stage I ovarian cancer following comprehensive surgical staging 
  Irvine, CA - 1/1/1993
• Early trends in CA-125 levels as predictors of response in a prospective trial in the treatment of advanced ovarian cancer 
  Las Vegas, NV - 1/1/1992
• Secondary cytoreduction in ovarian carcinoma 
  Minneapolis, MN - 1/1/1992
• Monoclonal antibodies in the managment of ovarian cancer 
  Orlando, FL - 1/1/1992
• Prognostic significance of her-2/Neu expressions in epithelial ovarian cancer: A multivariate analysis 
  San Antonio, TX, 1992 - 1/1/1992
• High resolution positron emission tomography of human ovarian cancer in nude rats using 124-I labeled monoclonal antibodies 
  Orlando, FL - 1/19/1991
• Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy 
  Orlando, FL - 1/18/1991
• Join now to see all

Other

• Hereditary aspects of ovarian cancer 
  Chu CS, Rubin SC, HOPE—News from The Ovarian Cancer Research Fund
  1/1/2002